NCT01636024View on ClinicalTrials.gov

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594

PHASE1CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
SafetyPharmacokineticsPharmacodynamics of AZD7594
Interventions
DRUG

AZD7594

Suspension inhaled via Spira nebuliser

DRUG

Placebo to match

Matching placebo inhaled via Spira nebuliser

Trial Locations (1)

Unknown

Research Site, London

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY